NO20043038L - Polymorfe former av klopidogrel-hydrogensulfat - Google Patents

Polymorfe former av klopidogrel-hydrogensulfat

Info

Publication number
NO20043038L
NO20043038L NO20043038A NO20043038A NO20043038L NO 20043038 L NO20043038 L NO 20043038L NO 20043038 A NO20043038 A NO 20043038A NO 20043038 A NO20043038 A NO 20043038A NO 20043038 L NO20043038 L NO 20043038L
Authority
NO
Norway
Prior art keywords
hydrogen sulfate
polymorphic forms
clopidogrel hydrogen
clopidogrel hydrogensulfate
clopidogrel
Prior art date
Application number
NO20043038A
Other languages
English (en)
Norwegian (no)
Inventor
Ramy Lidor-Hadas
Shlomit Wizel
Revital Lifshitz-Liron
Eti Kovaleski-Ishai
Sharon Avhar-Maydan
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/074,409 external-priority patent/US6767913B2/en
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of NO20043038L publication Critical patent/NO20043038L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Liquid Crystal Substances (AREA)
NO20043038A 2001-12-18 2004-07-16 Polymorfe former av klopidogrel-hydrogensulfat NO20043038L (no)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US34244001P 2001-12-18 2001-12-18
US34235101P 2001-12-21 2001-12-21
US34818202P 2002-01-11 2002-01-11
US10/074,409 US6767913B2 (en) 2001-12-18 2002-02-12 Crystal forms iii, iv, v, and novel amorphous form of clopidogrel hydrogensulfate, processes for their preparation, processes for the preparation of form i, compositions containing the new forms and methods of administering the new forms
US35915702P 2002-02-21 2002-02-21
PCT/US2002/040679 WO2003051362A2 (en) 2001-12-18 2002-12-18 Polymorphs of clopidogrel hydrogensulfate

Publications (1)

Publication Number Publication Date
NO20043038L true NO20043038L (no) 2004-09-09

Family

ID=27536010

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20043038A NO20043038L (no) 2001-12-18 2004-07-16 Polymorfe former av klopidogrel-hydrogensulfat

Country Status (18)

Country Link
EP (1) EP1467735B1 (de)
JP (2) JP2005514387A (de)
KR (1) KR100839136B1 (de)
CN (1) CN1620293A (de)
AT (1) ATE417051T1 (de)
AU (1) AU2002366383B2 (de)
CA (1) CA2470479A1 (de)
DE (1) DE60230327D1 (de)
ES (1) ES2316650T3 (de)
HR (1) HRP20040647A2 (de)
HU (1) HUP0402485A3 (de)
IL (1) IL162461A0 (de)
IS (1) IS7319A (de)
MX (1) MXPA04006088A (de)
NO (1) NO20043038L (de)
PL (1) PL370802A1 (de)
PT (1) PT1467735E (de)
WO (1) WO2003051362A2 (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ297472B6 (cs) * 2002-08-27 2006-12-13 Zentiva, A.S. Zpusob výroby clopidogrelu hydrogensulfátu krystalické formy I
GB2393181A (en) * 2002-09-19 2004-03-24 Cipla Ltd Amorphous clopidogrel
ITMI20022228A1 (it) * 2002-10-21 2004-04-22 Dinamite Dipharma S P A Sali di clopidogrel con acidi alchil-solforici.
AU2003285841A1 (en) * 2002-11-28 2004-06-18 Anpharm Przedsiebiorstwo Farmaceutyczne S.A. A process for the preparation of crystalline form 1 or clopidogrel hydrogen sulfate
AU2003216707A1 (en) * 2003-03-10 2004-09-30 Hetero Drugs Limited Amorphous clopidogrel hydrogen sulfate
US7872019B2 (en) 2003-03-12 2011-01-18 Cadila Healthcare Limited Polymorphs and amorphous form of (S)-(+)-clopidogrel bisulfate
KR20060026121A (ko) * 2003-07-02 2006-03-22 에지스 지오기스제르기아르 알티. 혈소판 응집 억제 약물의 무정형 형태를 제조하는 방법
HU0302029D0 (en) * 2003-07-02 2003-09-29 Egyt Gyogyszervegyeszeti Gyar Amorphous form of an anticoagulant agent
CA2530449C (en) 2003-07-02 2010-03-23 Egis Gyogyszergyar Rt. Process for the preparation of crystalline polymorph of a platelet aggregation inhibitor drug
DE10337773A1 (de) * 2003-08-13 2005-03-24 Krka Tovarna Zdravil, D.D. Kristallisation von festen Formen von Clopidogrel-Additionssalzen
PT1680430E (pt) 2003-11-03 2010-04-26 Cadila Healthcare Ltd Processos para a preparação da forma i de bissulfato de (s)-(+)-clopidogrel
CN1938319B (zh) * 2004-04-09 2010-05-12 韩美药品株式会社 结晶氯吡格雷萘磺酸盐或其水合物、其制备方法及含其的药物组合物
EP1740593B1 (de) 2004-04-19 2016-04-06 KRKA, tovarna zdravil, d.d., Novo mesto Verfahren zur herstellung der polymorphen form i von clopidogrelhydrogensulfat
KR20070012675A (ko) * 2004-04-20 2007-01-26 사노피-아벤티스 메틸(+)-(Ｓ)-α-(2-클로로페닐)-6,7-디히드로티에노[3,2-Ｃ]피리딘-5(4Ｈ) 아세테이트 히드로브로마이드, 클로피도그렐히드로브로마이드의 다형성 형태
CA2561006A1 (en) * 2004-04-20 2005-11-03 Sanofi-Aventis Clopidogrel salt and polymorphic forms thereof
WO2005117866A1 (en) * 2004-06-01 2005-12-15 Ivax Pharmaceuticals S.R.O. Amorphous clopidogrel hydrochloride and its antithrombotic use
EP1693375A1 (de) * 2005-02-21 2006-08-23 KRKA, tovarna zdravil, d.d., Novo mesto Verfahren zur Herstellung von Clopidrogel hydrogen sulfat in Form I
KR20070009851A (ko) * 2005-07-14 2007-01-19 씨제이 주식회사 클로피도그렐 황산수소염 함유 약학 조성물
US20090093635A1 (en) * 2006-03-09 2009-04-09 Sandor Garadnay PROCESS FOR MAKING POLYMORPH FROM I OF (S) - (+) -METHYL-ALPHA- (2-CHLOROPHENYL) -6, 7-DYHIDRO-THIENO- [3, 2-c] PYRIDINE-5 (4H) -ACETATE HYDROGEN SULFATE
SI22383A (sl) * 2006-09-22 2008-04-30 Krka, Tovarna Zdravil, D.D., Novo Mesto Nov postopek sinteze klopidogrela in nove oblike njegovih farmacevtsko sprejemljivih soli
HUP0600839A3 (en) * 2006-11-14 2008-09-29 Egis Gyogyszergyar Nyrt Solid pharmaceutical composition containing polymorph i of clopidogrel hydrogensulfate and process for the preparation thereof
KR101464482B1 (ko) * 2007-05-08 2014-11-26 경동제약 주식회사 클로피도그렐 황산수소염을 함유하는 약학적 조성물 및 그제조방법
EP2107061A1 (de) 2008-04-02 2009-10-07 Krka Tovarna Zdravil, D.D., Novo Mesto Herstellungsverfahren für optisch angereichertes Clopidogrel
KR101130445B1 (ko) * 2009-10-29 2012-03-27 동아제약주식회사 클로피도그랠 황산수소염 ⅰ형 제조방법
CN101962387B (zh) * 2010-09-13 2013-01-30 成都雅途生物技术有限公司 一种新结晶形态的氯吡格雷硫酸氢盐及其制备方法
CN102358743A (zh) * 2011-11-05 2012-02-22 江南大学 一种制备无定形氯吡格雷硫酸氢盐的简便方法
CN103006599A (zh) * 2012-12-31 2013-04-03 广州白云山天心制药股份有限公司 含氯化钠药物载体的抗凝血片剂及其制备方法
CN103408567B (zh) * 2013-07-18 2016-12-28 浙江普洛医药科技有限公司 一种制备硫酸氢氯吡格雷晶型ⅰ的方法
CN104610274B (zh) * 2013-11-05 2017-04-19 亚宝药业集团股份有限公司 一种i型氯吡格雷硫酸氢盐的制备方法
TWI665190B (zh) 2013-11-15 2019-07-11 阿克比治療有限公司 ｛［５－（３－氯苯基）－３－羥基吡啶－２－羰基］胺基｝乙酸之固體型式，其組合物及用途
CN104045653A (zh) * 2014-07-15 2014-09-17 苏州天马精细化学品股份有限公司 一种硫酸氢氯吡格雷的纯化方法
KR101710922B1 (ko) 2015-06-03 2017-02-28 경동제약 주식회사 클로피도그렐 황산염 결정형 i형의 제조방법
CN107163060B (zh) * 2017-05-24 2021-03-02 常州制药厂有限公司 一种硫酸氢氯吡格雷晶型ii制备方法
CN107337683B (zh) * 2017-08-16 2019-08-16 中荣凯特（北京）生物科技有限公司 一种噻吩并吡啶类衍生物硫酸氢盐的晶型ⅱ及其制备方法和应用
WO2020013305A1 (ja) * 2018-07-12 2020-01-16 有機合成薬品工業株式会社 クロピドグレル硫酸塩のｉ型結晶の製造方法
KR102220480B1 (ko) * 2019-02-13 2021-02-25 한국바이오켐제약 주식회사 클로피도그렐황산염의 제조방법 및 이를 포함하는 약학제제

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2623810B2 (fr) * 1987-02-17 1992-01-24 Sanofi Sa Sels de l'alpha-(tetrahydro-4,5,6,7 thieno(3,2-c) pyridyl-5) (chloro-2 phenyl) -acetate de methyle dextrogyre et compositions pharmaceutiques en contenant
FR2664276B1 (fr) * 1990-07-04 1992-10-23 Sanofi Sa Derive thienyl-2 glycidique, son procede de preparation et son utilisation comme intermediaire de synthese.
US5576328A (en) * 1994-01-31 1996-11-19 Elf Sanofi Method for the secondary prevention of ischemic events
FR2751540B1 (fr) * 1996-07-26 1998-10-16 Sanofi Sa Composition pharmaceutique antithrombotique
FR2769313B1 (fr) * 1997-10-06 2000-04-21 Sanofi Sa Derives d'esters hydroxyacetiques, leur procede de preparation et leur utilisation comme intermediaires de synthese
FR2779726B1 (fr) * 1998-06-15 2001-05-18 Sanofi Sa Forme polymorphe de l'hydrogenosulfate de clopidogrel
AU2002356430A1 (en) * 2002-12-09 2004-06-30 Hetero Drugs Limited A novel polymorph of clopidogrel hydrogen sulfate

Also Published As

Publication number Publication date
HUP0402485A3 (en) 2008-10-28
HUP0402485A2 (hu) 2005-04-28
HRP20040647A2 (en) 2005-04-30
CA2470479A1 (en) 2003-06-26
IS7319A (is) 2004-06-16
WO2003051362A3 (en) 2003-08-07
PT1467735E (pt) 2009-03-10
JP2005514387A (ja) 2005-05-19
MXPA04006088A (es) 2004-09-27
AU2002366383B2 (en) 2007-06-14
CN1620293A (zh) 2005-05-25
DE60230327D1 (de) 2009-01-22
AU2002366383A1 (en) 2003-06-30
KR20040066917A (ko) 2004-07-27
EP1467735A2 (de) 2004-10-20
JP2009108107A (ja) 2009-05-21
ATE417051T1 (de) 2008-12-15
WO2003051362A2 (en) 2003-06-26
ES2316650T3 (es) 2009-04-16
PL370802A1 (en) 2005-05-30
KR100839136B1 (ko) 2008-06-20
EP1467735A4 (de) 2005-11-23
EP1467735B1 (de) 2008-12-10
IL162461A0 (en) 2005-11-20

Similar Documents

Publication Publication Date Title
DE60230327D1 (de) Polymorphe von clopidogrel-hydrogensulfat
AU2003279337A1 (en) Direct process for the manufacture of tetraalkylammonium tetrafluoroborate-containing electrolyte compositions
MXPA06001494A (es) Compuestos de piramidina condensados como inhibidores de canales ionicos gatillados por tension.
DE60108754D1 (de) Substituierte bizyklische derivate für die behandlung von unnormalem zellwachstum
WO2005003320A3 (en) Neuronal differentiation of stem cells
IL172357A0 (en) Method for the production of substituted 3-aryl-butyl amine compounds
NO20041379L (no) Enzymatiske prosesser for fremstilling av 4-substituerte 3-hydroksysmorsyrederivater
EA200600621A1 (ru) Производные тетрагидронафталина, способ их получения и их применение в качестве противовоспалительных средств
CY1108808T1 (el) Ενωσεις μοτιλιδης
ATE393764T1 (de) Polymorphe formen von valsartan
MX2007010045A (es) Pirazolopirimidinas.
FR2846964B1 (fr) Procede de fabrication de 1,2-epoxy-3-chloropropane
WO2005035537A3 (en) Substituted tricyclic heterocycles and their uses
TW200745137A (en) Thieno[2,3-b]pyridine-5-carbonitriles as protein kinase inhibitors
WO2006066950A3 (de) Tricyclische aminoalkohole, verfahren zu ihrer herstellung und ihre verwendung als entzündungshemmer
NO20033408D0 (no) Fremgangsmåte for fremstilling av krystallinske nanopartikler
BR0318521A (pt) arilindenopiridinas e arilindenopirimidinas e métodos terapêuticos e profiláticos relacionados
PL370911A1 (pl) Sposoby wytwarzania podstawionych bicyklicznych pochodnych do leczenia nieprawidłowego wzrostu komórek
HRP20051005A2 (en) Process for the preparation of nonpeptide substituted spirobenzoazepine derivatives
ATE335739T1 (de) Cak inhibitoren und deren verwendungen
MX2007002833A (es) Derivados de alquiliden-tetrahidronaftaleno, procedimiento para su preparacion y su uso como antiinflamatorios.
AU2002363829A1 (en) Method for producing stem cells with increased developmental potential
ATE403660T1 (de) Benzo 4,5 thieno 3,2-b pyran-2-on enthaltende duftstoffzusammensetzungen
TW200609226A (en) New isobenzoxazinones and their use as ultraviolet light absorbers
BRPI0415038A (pt) derivados de imidazo (4,5-b) piridina como inibidores sem ser da sintase que podem ser induzidos

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application